Research programme: carbon monoxide based therapeutics - Hillhurst Biopharmaceuticals

Drug Profile

Research programme: carbon monoxide based therapeutics - Hillhurst Biopharmaceuticals

Alternative Names: HBI 002; HBI 137

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Hillhurst Biopharmaceuticals
  • Class Inorganic carbon compounds
  • Mechanism of Action Heme oxygenase 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries; Delayed graft function; Multiple sclerosis; Sickle cell anaemia
  • Research Inflammation

Most Recent Events

  • 14 Jun 2017 Hillhurst Biopharmaceuticals receives SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for HBI-002 development in Delayed graft function
  • 01 Jun 2017 Preclinical trials in Delayed graft function in USA (PO) before June 2017
  • 24 May 2016 Hillhurst Biopharmaceuticals receives SBIR grant from National Heart, Lung and Blood Institute (NHLBI) for HBI 002 development at preclinical stage in Sickle cell disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top